By Sabela Ojea
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study.
The pharmaceutical company on Thursday said that the safety profile of Korlym in the study was consistent with the medication's label and no new side effects or adverse events were identified.
Complete results from the study will be presented at a medical conference next year, the company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 12, 2024 17:47 ET (22:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments